Both these products contain elvitegravir 150mg, cobicistat 150mg and emtricitabine 200mg, as well as 10mg of tenofovir alafenamide (Genvoya) or 245mg tenofovir disoproxil (Stribild).
This risk is the subject of the latest MHRA Drug Safety Update which notes that a review of safety data and the published literature has not to date identified any cases of mother to child HIV-1 transmission in women taking regimens containing elvitegravir/cobicistat during the second and third trimesters of pregnancy. However, due to the theoretical risk, therapy with elvitegravir/cobicistat should not be initiated during pregnancy and women who are pregnant and taking elvitegravir/cobicistat should be switched to an alternative regimen.